^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (HER2 inhibitor, γδ TCR modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
654 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Published date:
11/04/2023
Excerpt:
The ongoing clinical trial (NCT04727151) is evaluating the safety and preliminary anti-tumor activity of TAC01-HER2 treatment of HER2+ solid tumors….In Phase II, dose expansion groups will further evaluate the efficacy, safety, and pharmacokinetics of the optimal TAC01-HER2 dose in gastric/GEJ tumors....For gastric/GEJ subjects of the same Cohorts, DCR was 83%. 3 months after TAC01-HER2 infusion, DCR was 33.3% for all subjects of Cohorts 2–4 and 50% for gastric/GEJ subjects. Two patients had a partial response (PR). At Cohort 4, a PR was observed in a subject with GEJ (HER2 2+, FISH+) with 100% reduction of target lesion.
DOI:
http://dx.doi.org/10.1136/jitc-2023-SITC2023.0654
Trial ID:
